FDA 483 - Lupin Limited - July 17, 2025

**FDA 483 Summary for Lupin Limited**

**Inspection Dates:** July 8-17, 2025 **Company:** Lupin Limited **Location:** Pithampur, Madhya Pradesh, India **Type of Establishment:** Human Drug Manufacturer

**Main Violations/Issues:**

1. **Microbiological Contamination Prevention:** Procedures to prevent contamination in sterile drug products were not adhered to. Specific deviations included operators reaching over open vials and bottles without removing exposed containers, inadequate environmental monitoring in critical areas, and improper gowning standards.

2. **Aseptic Process Simulation Deficiencies:** During media fills, operators were observed performing interventions that did not accurately simulate actual production conditions. Issues included improper personnel monitoring techniques and interventions that did not reflect worst-case scenarios.

3. **Aseptic Personnel Qualification:** The qualification process for aseptic personnel lacked specificity in required activities during media fills, leading to potential inadequacies in operator competency.

4. **Air Supply and Flow Issues:** Aseptic processing areas showed deficiencies in air supply, with smoke studies revealing turbulent airflow patterns that compromised the demonstration of proper unidirectional airflow.

**Regulatory Framework:** The observations are based on FDA regulations concerning the manufacture of sterile drug products, emphasizing the need for strict adherence to procedures that ensure product safety and efficacy.

**Required Actions:** Lupin Limited must address the identified deficiencies by implementing corrective actions to ensure compliance with FDA standards. This includes revising procedures to prevent contamination, enhancing operator training and qualification processes, and improving airflow studies to ensure proper aseptic conditions. The company is encouraged to discuss objections or corrective actions with the FDA and submit relevant information for review.